Profiling Asthma Immune Responses to Improve Therapeutics (PAIR-IT) (PAIR-IT)
Brief description of study
Researchers at the University of Pennsylvania in the Department of Biostatistics, Epidemiology and Informatics and the Division of Pulmonary, Allergy, and Critical Care Medicine are conducting a study to better understand how blood immune cells, which are involved in allergies and asthma, change in asthma patients who take asthma biologic drugs. Understanding these blood immune cell changes may help us understand who will best respond to biologic drugs.
Detailed description of study
If you agree to join the study, the care you receive will not change. Your physician will choose the type of biologic drug and dose in accordance with current clinical guidelines and what they think will be most helpful to you. If you join, you will be asked to:
•Complete a blood draw and questionnaire before you come in for your first biologic injection
•Complete another blood draw and questionnaire after one month of your first biologic injection
•After each visit, you will be paid $50
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: Between 18 Years - 99 Years
-
Gender: All
You may be eligible for this study if you are 18 years or older and:
•You have severe asthma
•A Penn Medicine asthma specialist has prescribed one of the following biologics to you:
-Dupixent (Dupilumab)
-Nucala (Mepolizumab)
-Xolair (Omalizumab)
-Tezspire (Tezepelumab)
